APG Asset Management N.V. Increases Stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

APG Asset Management N.V. increased its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 795.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 125,000 shares of the medical equipment provider's stock after buying an additional 111,036 shares during the period. APG Asset Management N.V. owned 0.06% of Zimmer Biomet worth $12,751,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of ZBH. CKW Financial Group increased its stake in shares of Zimmer Biomet by 11.7% in the 4th quarter. CKW Financial Group now owns 955 shares of the medical equipment provider's stock valued at $101,000 after purchasing an additional 100 shares during the last quarter. Romano Brothers AND Company boosted its stake in shares of Zimmer Biomet by 1.1% during the fourth quarter. Romano Brothers AND Company now owns 9,466 shares of the medical equipment provider's stock valued at $1,000,000 after purchasing an additional 102 shares in the last quarter. Dorsey & Whitney Trust CO LLC raised its holdings in Zimmer Biomet by 2.3% in the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 4,594 shares of the medical equipment provider's stock valued at $485,000 after buying an additional 102 shares during the last quarter. M&T Bank Corp grew its holdings in Zimmer Biomet by 0.4% during the 4th quarter. M&T Bank Corp now owns 26,827 shares of the medical equipment provider's stock worth $2,834,000 after acquiring an additional 108 shares during the last quarter. Finally, Dakota Wealth Management grew its stake in shares of Zimmer Biomet by 1.3% in the fourth quarter. Dakota Wealth Management now owns 9,620 shares of the medical equipment provider's stock worth $1,016,000 after purchasing an additional 122 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company's stock.

Remove Ads

Insider Activity

In related news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total transaction of $150,649.20. Following the completion of the transaction, the senior vice president now directly owns 8,768 shares of the company's stock, valued at $915,379.20. This trade represents a 14.13 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 0.95% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on ZBH shares. Needham & Company LLC reissued a "hold" rating on shares of Zimmer Biomet in a research report on Friday, February 7th. JPMorgan Chase & Co. raised Zimmer Biomet from a "neutral" rating to an "overweight" rating and lifted their price objective for the stock from $125.00 to $128.00 in a research report on Tuesday, December 17th. Raymond James cut their target price on Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating on the stock in a research report on Friday, February 7th. Royal Bank of Canada cut their price target on Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating on the stock in a report on Friday, February 7th. Finally, Stifel Nicolaus increased their price target on Zimmer Biomet from $130.00 to $138.00 and gave the stock a "buy" rating in a report on Thursday, January 23rd. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $124.15.

Zimmer Biomet Trading Down 0.5 %

Shares of ZBH traded down $0.51 during mid-day trading on Monday, reaching $101.84. The company's stock had a trading volume of 2,164,629 shares, compared to its average volume of 1,633,558. The stock has a market cap of $20.27 billion, a PE ratio of 22.89, a P/E/G ratio of 1.95 and a beta of 0.84. The company's fifty day moving average price is $106.31 and its two-hundred day moving average price is $107.03. Zimmer Biomet Holdings, Inc. has a 52 week low of $97.69 and a 52 week high of $127.32. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the previous year, the firm posted $2.20 earnings per share. On average, analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.94%. The ex-dividend date is Monday, March 31st. Zimmer Biomet's dividend payout ratio (DPR) is presently 21.57%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.